TMC
ACHN

Trellus Management Company’s Achillion Pharmaceuticals ACHN Stock Holding History

Trellus Management Company’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-33,400
Closed -$273K – 132
2013
Q2 		$273K Buy
+33,400
New +$255K 0.35% 81

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Trellus Management Company's ACHN Position: Q3 2013 in Review

Trellus Management Company sold out of Achillion Pharmaceuticals (ACHN) in Q3 2013, closing a stake of 33,400 shares — an estimated $273K sold.

Trellus Management Company first reported a position in ACHN in Q2 2013 and held it in 1 quarter. The position peaked at $273K in Q2 2013. 102 funds tracked by Wall St. Rank hold ACHN as of Q3 2013.

  • Trellus Management Company reported no remaining Achillion Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Trellus Management Company sold 33,400 Achillion Pharmaceuticals shares in Q3 2013, an estimated $273K.
  • Trellus Management Company first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Trellus Management Company's Achillion Pharmaceuticals position peaked at $273K in Q2 2013.
  • 102 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2013.

Based on Trellus Management Company's 13F filing for Q3 2013, filed 14 Nov 2013.